208 related articles for article (PubMed ID: 15811906)
1. Angioedema associated with aspirin and rofecoxib.
Marshall LL
Ann Pharmacother; 2005 May; 39(5):944-8. PubMed ID: 15811906
[TBL] [Abstract][Full Text] [Related]
2. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
Ann Allergy Asthma Immunol; 2005 Jan; 94(1):34-8. PubMed ID: 15702813
[TBL] [Abstract][Full Text] [Related]
3. Urticaria and angioedema from cyclooxygenase-2 inhibitors.
Kelkar PS; Butterfield JH; Teaford HG
J Rheumatol; 2001 Nov; 28(11):2553-4. PubMed ID: 11708434
[TBL] [Abstract][Full Text] [Related]
4. Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease.
Woessner KM; Simon RA; Stevenson DD
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):339-44. PubMed ID: 15521369
[TBL] [Abstract][Full Text] [Related]
5. Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria.
Asero R
Ann Allergy Asthma Immunol; 2006 Aug; 97(2):187-9. PubMed ID: 16937749
[TBL] [Abstract][Full Text] [Related]
6. Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs.
Nettis E; Colanardi MC; Ferrannini A; Tursi A
Ann Allergy Asthma Immunol; 2005 Jan; 94(1):29-33. PubMed ID: 15702812
[TBL] [Abstract][Full Text] [Related]
7. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma.
Stevenson DD; Simon RA
J Allergy Clin Immunol; 2001 Jul; 108(1):47-51. PubMed ID: 11447381
[TBL] [Abstract][Full Text] [Related]
8. The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance.
Bavbek S; Celik G; Ediger D; Mungan D; Demirel YS; Misirligil Z
J Asthma; 1999 Dec; 36(8):657-63. PubMed ID: 10609620
[TBL] [Abstract][Full Text] [Related]
9. Intracranial hypertension induced by rofecoxib.
Jacob S; Rajabally YA
Headache; 2005 Jan; 45(1):75-6. PubMed ID: 15663617
[TBL] [Abstract][Full Text] [Related]
10. Lichenoid drug eruption probably associated with rofecoxib.
Abu-Shraie NA; Alfadley AA
Ann Pharmacother; 2004 May; 38(5):795-8. PubMed ID: 15026562
[TBL] [Abstract][Full Text] [Related]
11. Adverse oral reactions associated with the COX-2 inhibitor rofecoxib.
Bagán JV; Thongprasom K; Scully C
Oral Dis; 2004 Nov; 10(6):401-3. PubMed ID: 15533219
[TBL] [Abstract][Full Text] [Related]
12. [Aspirin-induced angioedema of the nape of the neck with naproxen cross-reaction: a case report].
Ghislain PD; Ghislain E
Ann Med Interne (Paris); 2000 May; 151(3):227-9. PubMed ID: 10896977
[TBL] [Abstract][Full Text] [Related]
13. [Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents].
Zollner TM; Ahlbach S; Kaufmann R; Boehncke WH
Dtsch Med Wochenschr; 2001 Apr; 126(14):386-8. PubMed ID: 11332239
[TBL] [Abstract][Full Text] [Related]
14. Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs.
Asero R
Clin Exp Allergy; 2005 Jun; 35(6):713-6. PubMed ID: 15969659
[TBL] [Abstract][Full Text] [Related]
15. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
16. [Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs)].
Boehncke S; Boehncke WH
Dtsch Med Wochenschr; 2005 Oct; 130(40):2249-52. PubMed ID: 16208597
[TBL] [Abstract][Full Text] [Related]
17. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib.
Bavbek S; Celik G; Ozer F; Mungan D; Misirligil Z
J Asthma; 2004 Feb; 41(1):67-75. PubMed ID: 15046380
[TBL] [Abstract][Full Text] [Related]
18. Rofecoxib, as a safe alternative for acetyl salicylic acid/nonsteroidal anti-inflammatory drug-intolerant patients.
Bavbek S; Celik G; Pasaoglu G; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(1):57-62. PubMed ID: 16599250
[TBL] [Abstract][Full Text] [Related]
19. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG
Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867
[TBL] [Abstract][Full Text] [Related]
20. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter.
Davies NM; Jamali F
J Pharm Pharm Sci; 2004 Oct; 7(3):332-6. PubMed ID: 15576013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
